Abstract: The present invention relates to a novel biomarker for predicting prognosis of treatment of HER2-positive breast cancer and the use thereof. The present invention presents the novel biomarker for predicting prognosis of treatment of HER2-positive breast cancer, and provides a composition and a kit for predicting prognosis of treatment of HER2-positive breast cancer, which can detect or measure the biomarker in HER2 early-positive breast cancer patients to whom neoadjuvant chemotherapy is applicable. Furthermore, according to the present invention, it is possible to select a patient-specific therapy by quickly and accurately determining the prognosis of drug treatment of the patient.

Abstract: Provided is a colorectal cancer-specific methylation biomarker for diagnosing colorectal cancer. Since a gene marker according to an embodiment exhibits a specific methylation pattern in colorectal cancer tissue, it can be usefully used as a methylation marker for diagnosing colorectal cancer, thereby increasing the cure rate of colorectal cancer by early diagnosis and treatment of colorectal cancer.

Abstract: The present disclosure relates to a method of predicting therapeutic response or prognosis of an anticancer drug for metastatic breast cancer, and treating HR+/HER2? metastatic breast cancer. When the biomarker of an embodiment of the present disclosure is used as a marker for predicting therapeutic response or prognosis of an anticancer drug for metastatic breast cancer of a specific type, it is possible to predict therapeutic response or prognosis of a specific anticancer drug, and accordingly, a therapeutic method currently being developed may be applied at an early stage to maximize the treatment effect.

Abstract: The present disclosure relates to a method of predicting therapeutic response or prognosis of an anticancer drug for metastatic breast cancer, and treating HR+/HER2? metastatic breast cancer. When the biomarker of an embodiment of the present disclosure is used as a marker for predicting therapeutic response or prognosis of an anticancer drug for metastatic breast cancer of a specific type, it is possible to predict therapeutic response or prognosis of an anticancer drug, and accordingly, a therapeutic method suitable for a patient may be applied to maximize the treatment effect.

Abstract: Provided are a method and a device for encapsulating a cell in droplet for single-cell analysis, or a method and a device for forming droplet for single-cell analysis. According to the method and the device of one aspect, by using the effects of inertial ordering, not only a ratio at which one cell is encapsulated in one droplet is increased, but also a yield of generating droplet is improved.

Abstract: Provided is a colorectal cancer-specific methylation biomarker for diagnosing colorectal cancer. Since a gene marker according to an embodiment exhibits a specific methylation pattern in colorectal cancer tissue, it can be usefully used as a methylation marker for diagnosing colorectal cancer, thereby increasing the cure rate of colorectal cancer by early diagnosis and treatment of colorectal cancer.

Abstract: The present invention relates to a method of analyzing a corrected TMB and a method for predicting a response to immune checkpoint inhibitors in a cancer patient using the same. According to a method, a computer-readable recording medium and an analyzing apparatus, for providing information according to an aspect, since the corrected TMB of the present invention is markedly highly predictive of the response to cancer immunotherapy in the cancer patient, compared to the conventional TMB, a patient group predicted to show a therapeutic effect can be selected and an appropriate treatment can be administered, thereby alleviating pain and treatment costs from the cancer patient.

Abstract: Provided are a method for generating a distribution of background allele frequency in sequencing data obtained from a cell-free nucleic acid, a frequency distribution matrix of background alleles obtained by the method, and a method of detecting a variation in the cell-free nucleic acid using the matrix. According to the method, to remove germline variations, sequencing data of a nucleic acid isolated from a cell of a test subject itself may be used to generate a distribution of background allele frequency in the sequencing data obtained from the cell-free nucleic acid, and thus there are advantages in terms of reducing costs and time.

Abstract: Provided are a gene panel for personalized medicine, a method of constructing the same, and a personalized treatment method using the same. In one aspect, the method of constructing the gene panel, based on an individual's genomic sequence mutation information, may detect gene mutations related to intractable diseases including cancer, and therefore, personalized treatments considering cancer progression or change in patients and treatment models of the diseases may be constructed.

Abstract: Provided are biomarkers that are sensitive or resistant to poziotinib therapy for cancer and methods of using the biomarkers.

Abstract: Provided are a method and a device for encapsulating a cell in droplet for single-cell analysis, or a method and a device for forming droplet for single-cell analysis. According to the method and the device of one aspect, by using the effects of inertial ordering, not only a ratio at which one cell is encapsulated in one droplet is increased, but also a yield of generating droplet is improved.

Abstract: Disclosed are a composition for the diagnosis of exposure to electromagnetic radiation, comprising an agent capable of measuring the expression level of the diagnostic marker, a diagnosis kit comprising the same, a method for detecting the diagnostic marker, and a method for the diagnosis of exposure to electromagnetic radiation. The diagnostic markers are very useful for monitoring and diagnosing exposure to electromagnetic fields, and can be used as instruments by which physiological mechanisms incurred upon electromagnetic radiation exposure are examined.

Abstract: Disclosed are a composition for the diagnosis of exposure to electromagnetic radiation, comprising an agent capable of measuring the expression level of the diagnostic marker, a diagnosis kit comprising the same, a method for detecting the diagnostic marker, and a method for the diagnosis of exposure to electromagnetic radiation. The diagnostic markers are very useful for monitoring and diagnosing exposure to electromagnetic fields, and can be used as instruments by which physiological mechanisms incurred upon electromagnetic radiation exposure are examined.

Abstract: Disclosed are a composition for the diagnosis of exposure to electromagnetic radiation, comprising an agent capable of measuring the expression level of the diagnostic marker, a diagnosis kit comprising the same, a method for detecting the diagnostic marker, and a method for the diagnosis of exposure to electromagnetic radiation. The diagnostic markers are very useful for monitoring and diagnosing exposure to electromagnetic fields, and can be used as instruments by which physiological mechanisms incurred upon electromagnetic radiation exposure are examined.

Abstract: The present invention relates to nucleic acid sequences and proteins involved in senescence and particularly, to nucleic acid sequences and proteins including amphiphysin and caveolin involved in cellular senescence and their use.

Abstract: The present invention relates to nucleic acid sequences and proteins involved in senescence and particularly, to nucleic acid sequences and proteins including amphiphysin and caveolin involved in cellular senescence and their use.

Abstract: Agents and method are described for inducing apoptosis in normal and diseased cells by antagonizing the interaction between onconeural antigens and apoptosis-inducing proteins, such as transcription factors. The antagonism of the interaction leads to increased bioavailability of the protein, which then directly or indirectly induces cell cycle genes. In dysproliferative cells, such gene activation and induction of cell cycle genes leads to apoptosis and death of dysproliferative cells. Therapies are directed to the treatment of diseases such as cancer. Normal cells, such as germ cells, may be treated by the agents to undergo apoptosis, for example, in the induction of sterility. Methods for the identification of suitable agents of the present invention are described by determining the extent of interference of binding between onconeural antigens and their fragments and apoptosis-inducing proteins and their fragments, in cell-free and cell-based assays.

Abstract: The present invention relates to a transgenic mouse deficient in T-cells, which is provided by fusing human heat shock protein (Hsp) gene with H2K promoter and transferring it to a mouse. Transgenic mouse line with a shrunken thymus and edficient in T-cells not having mature T-cells can be obtained.